IQVIA Laboratories offers a range of genomic services to support drug discovery, precision medicine and clinical development. There are several advantages to incorporating genomic testing into immuno-oncology clinical trials. Watch this video to see Victor Weigman, IQVIA Laboratories Translational Genomics, discuss how incorporating genomic testing facilitates research and clinical trial design to realize genomics-based medicine. You’ll also learn how genomic testing expands insight into more treatment options based on a patient’s tumor classification.
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
